RxDoctor Payments Data

John Layher, MD

Cardiovascular Disease · Athens, GANPI 1629076583

Payments from drug & device makers

$124in general payments, 2019–2025

Across 5 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$75
  • Elutia, Inc.$30
  • E.r. Squibb & Sons, L.L.C.$14
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5

What the payments were for

  • Food & beverage$4940%
  • Education$7560%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$124 in reported general payments places this provider in the 10th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$262,470
Medicare patients
1,215
Services billed
3,914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban765$980,024
VyndamaxTafamidis16$680,365
EntrestoSacubitril/Valsartan136$194,782
XareltoRivaroxaban150$179,725
JardianceEmpagliflozin101$120,927
Repatha SureclickEvolocumab109$120,293
FarxigaDapagliflozin Propanediol80$104,614
VascepaIcosapent Ethyl53$35,314
Praluent PenAlirocumab26$21,183
Valsartan376$8,853
Metoprolol Succinate677$8,725
Atorvastatin Calcium768$7,710
Ezetimibe354$7,002
Rosuvastatin Calcium457$5,870
Ranolazine ErRanolazine42$5,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$75$104,61480 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →